Ambit Biosciences
Ambit Biosciences is engaged in the development of small molecule kinase inhibitors for the treatment of cancer and inflammatory disease.
Business Model:
Revenue: $9M
Employees: 11-50
Rankings
Industries / Tags:
Detailed Ambit Biosciences Information
Ambit Biosciences was acquired by
Daiichi Sankyo.
The acquisition happend on 2014-09-29.
Details of the transaction were not public
Acquirer
Geographic Data
Address: 11080 Roselle St
City: San Diego
State: CA
Zip: 92121
Country: US
Financial Info
Stage:
series unknown
Raised Last:
$50M
Raised Total:$152M
Social
Metrics
0Website Global Rank
0Website Monthly Traffic
Twitter Followers
Description
Ambit Biosciences is engaged in the development of small molecule kinase inhibitors for the treatment of cancer and inflammatory disease.
Contact Phone:
+18583342100
Contact Email:
Ambit Biosciences went public on 5/16/2013 on the NASDAQ
Listed Exchange:
NASDAQ
IPO Date:
5/16/2013
IPO Valuation:
$142M
Ticker Symbol:
AMBI
Amount Raised:
$65M
Live
Opened: -/share
| EBITDA | - |
| Total Cash | - |
| Total Debt | - |
| Total Revenue | - |
| Total Profit (Gross) | - |
| PE Ratio | - |
Startup Industries
Startup Locations
Portfolio Current Status
Portfolio Employee Count
| Announced Date | Name | Price |
|---|
Employee Departments
Employee States
|
|
Revenue: 0 - 100000 Employees: Industry: Software |
Details
|
|
|
Revenue: 0 - 100000 Employees: 51 - 500 Industry: Education |
Details
|
|
|
Revenue: 0 - 100000 Employees: 1 - 10 Industry: Blockchain |
Details
|
|
|
Revenue: 0 - 100000 Employees: 11 - 50 Industry: Industrial |
Details
|
|
|
Revenue: 0 - 100000 Employees: 1 - 10 Industry: Advertising |
Details
|
